In silico Screening and Identification of Natural Compound Sophoraflavanone G as Potential Human Sodium-Glucose Cotransporter 2 Inhibitor

Abstract

Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance, and it is hitherto incurable. Among different therapeutic modalities, glucose co-transporter (SGLT) inhibitors have gained prominence. In the current study, we have screened natural compounds as potential SGLT inhibitor and compared with conventional gliflozin drugs. We have selected human SGLT 1 and 2 sequences modeled by homology modeling using SWISS-MODEL server, stability analysis was performed in silico. We used CDOCKER to dock the selected gliflozin drugs and natural compounds with SGLT 1 and 2. We further checked adsorption, distribution, metabolism, excretion, and toxicity using ADMETSAR tools and identified Sophoraflavonone G as a potential natural compound with good binding energy and drug-like characteristics. The molecular dynamic simulation revealed sophoraflavonone G binds with SGLT2 and forms a stable complex.